Narrow your search

Library

LUCA School of Arts (3)

Odisee (3)

Thomas More Kempen (3)

Thomas More Mechelen (3)

UCLL (3)

VIVES (3)

FARO (2)

KU Leuven (2)

UGent (2)

ULB (2)

More...

Resource type

book (3)


Language

English (3)


Year
From To Submit

2022 (1)

2019 (1)

2018 (1)

Listing 1 - 3 of 3
Sort by

Book
Research of Pathogenesis and Novel Therapeutics in Arthritis
Author:
ISBN: 3038970662 3038970654 Year: 2019 Publisher: MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

Arthritis has a high prevalence globally and includes over 100 different types, the most common of which are rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and inflammatory arthritis. The exact etiology of arthritis remains unclear and no cure exists. Anti-inflammatory drugs are commonly used in the treatment of arthritis but are associated with significant side effects. Novel modes of therapy and additional prognostic biomarkers are urgently needed for arthritis patients. This book summarizes and discusses the global picture of the current understanding of arthritis.

Keywords

receptor activator of nuclear factor ?B --- infliximab --- tripterine --- triptolide --- osteoblast --- tumor necrosis factor-alpha --- synovial cell --- anti-arthritis --- biosimilars --- Epstein-Barr virus --- cytokines --- SOX9 --- parathyroid hormone --- nitric oxide --- rat --- etanercept --- angiogenesis --- glycosylation --- mitogen activated protein kinase --- Th9 lymphocytes --- rheumatoid arthritis --- IL-6 --- clodronate --- bone erosion --- mesenchymal stem cells --- collagen-induced arthritis --- biological --- gene expression --- inflammatory arthritis --- osteoarthritis --- fraxinellone --- nuclear factor kappa B --- messenger RNA --- inflammation --- miRNA --- disease-modifying --- adipokines --- WNT --- glycoprotein 42 --- miR-199a-5p --- proliferation --- next-generation sequencing --- collagen --- osteoarthritis (OA) --- experimental arthritis --- bone morphogenetic protein --- TNF-? --- computational modeling --- basic research --- osteoclast --- therapeutics --- certolizumab pegol --- chondrocytes --- progenitor cells --- adjuvant arthritis --- adalimumab --- triterpenoid --- sclareol --- TNF? --- fibroblast growth factor 2 --- antibodies --- osteoblasts --- molecular pathology --- Th17 --- immunology --- obesity --- visfatin --- articular cartilage --- autoimmune --- biomarkers --- celastrol --- MAPK --- disease pathways --- IL1? --- arthritis --- bioinformatics --- anticitrullinated peptide antibodies --- drug delivery system --- antagonists --- shared epitope --- pathology --- SMA- and MAD-related protein --- small-molecule inhibitor --- transforming growth factor ? --- mice --- golimumab --- spinal fusion --- antirheumatic drug --- early osteoarthritis --- stem cell --- rheumatoid factor --- therapeutic antibody --- bisphosphonate --- osteoclastogenesis --- interleukin --- spondyloarthropathies --- clinical translation --- therapy --- Traditional Chinese medicine --- chemokines --- structure --- cell signaling --- microRNA


Book
Vaccines, medicines and COVID-19 : how can WHO be given a stronger voice?
Author:
ISBN: 3030891259 3030891240 Year: 2022 Publisher: Cham : Springer International Publishing : Imprint: Springer,

Loading...
Export citation

Choose an application

Bookmark

Abstract

This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate — particularly in relation to drugs and vaccines — that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.

Keywords

COVID-19 (Disease) --- Medical policy. --- Vaccines. --- Social aspects. --- 2019-nCoV disease --- 2019 novel coronavirus disease --- Coronavirus disease-19 --- Coronavirus disease 2019 --- COVID-19 virus disease --- COVID19 (Disease) --- Novel coronavirus disease, 2019 --- SARS coronavirus 2 disease --- SARS-CoV-2 disease --- Coronavirus infections --- Respiratory infections --- Biologicals --- Health care policy --- Health policy --- Medical care --- Medicine and state --- Policy, Medical --- Public health --- Public health policy --- State and medicine --- Science and state --- Social policy --- Government policy --- COVID-19 Coronavirus pandemic --- access to affordable essential medicines --- Vaccine nationalism and vaccine safety --- World Health Organization reform --- Biosimilars and biotherapeutics --- COVAX Facility --- COVID-19 diagnostics --- Global health preparedness --- Article 19 of the WHO Constitution --- access to COVID-19 tools (ACT) accelerator --- Framework Convention on Tobacco Control (FCTC) --- Inter-Governmental Working Group (IGWG) --- Patentability criteria --- Pharmaceutical sovereignty --- Research and Development (R&D) --- Universal Health Coverage (UHC) --- World Health Assembly (WHA) --- World Trade Organization (WTO) --- non-governmental organization (NGOs) --- Open Access --- Medicine, Preventive. --- Health promotion. --- Vaccines --- Biomaterials. --- Public health. --- Health Promotion and Disease Prevention. --- Health Policy. --- Biomaterials-Vaccines. --- Public Health. --- Biotechnology. --- Community health --- Health services --- Hygiene, Public --- Hygiene, Social --- Public health services --- Public hygiene --- Social hygiene --- Health --- Human services --- Biosecurity --- Health literacy --- Medicine, Preventive --- National health services --- Sanitation --- Vaccine biotechnology --- Biotechnology --- Health promotion programs --- Health promotion services --- Promotion of health --- Wellness programs --- Preventive health services --- Health education --- Disease prevention --- Diseases --- Prevention of disease --- Preventive medicine --- Pathology --- Preventive medicine physicians --- Prevention --- COVID-19 Pandemic, 2020 --- -Political aspects. --- -COVID-19 --- Pandèmia de COVID-19, 2020 --- -Vacunes --- Condicions socials --- Political aspects. --- COVID-19 Pandemic, 2020-2023. --- COVID-19

Listing 1 - 3 of 3
Sort by